PCSK9 Inhibitor Side Effects
PCSK9 inhibitors (alirocumab and evolocumab) are generally well tolerated with a favorable safety profile, with the most common side effects being mild injection site reactions, nasopharyngitis, and influenza-like symptoms. 1, 2, 3
Common Side Effects
Injection Site Reactions
- Most frequent adverse effect occurring in <5% of patients
- Typically mild intensity (pain, bruising, hemorrhage, erythema)
- No cumulative effect with continued treatment
- Relatively infrequent compared to other injectable therapies 1, 4, 5
Upper Respiratory Symptoms
- Nasopharyngitis (most common)
- Upper respiratory tract infections
- Influenza and influenza-like illness 6, 2, 3
Musculoskeletal Effects
- Myalgia slightly more frequent with alirocumab compared to placebo
- Back pain and arthralgia reported
- Muscle-related adverse events comparable to ezetimibe in statin-intolerant patients 1
- No increased risk of rhabdomyolysis 7
Serious Adverse Events - Reassuring Data
Neurocognitive Function
- Small, nonsignificant increase in neurocognitive events reported initially 1
- EBBINGHAUS trial specifically evaluated cognitive function and found no detriment, even with LDL-C levels <25 mg/dL 4
- No increased risk of neurocognitive dysfunction confirmed in meta-analyses 8, 9, 7
Diabetes-Related Effects
- No increased risk of new-onset diabetes 8, 9, 7
- Evolocumab may worsen existing diabetes in the first 24 weeks of treatment (highest risk in first 12 weeks), but this effect diminishes with therapy >24 weeks 8
- Alirocumab showed reduced risk of diabetes-related adverse events in some analyses 9
- No change in glycated hemoglobin levels over time 4
Hepatic and Muscle Toxicity
- No increase in liver enzyme elevations 8, 9, 7
- No increase in creatine kinase elevation 8, 7
- No evidence of hepatotoxicity 4
Ophthalmologic Events
- Small, nonsignificant increase in ophthalmologic events reported for alirocumab 1
Cardiovascular Safety
- No evidence of increased hemorrhagic stroke risk 4
- Rare reports of atrial fibrillation in complex patients, though no definitive association established 10
Very Low LDL-C Levels Safety
No excess adverse events in patients achieving LDL-C <25 mg/dL or even <15 mg/dL over 78 weeks of treatment 1, 4. This is particularly important as many patients on PCSK9 inhibitors achieve these very low levels.
Mortality and Serious Events
- PCSK9 inhibitors do not increase all-cause mortality or cardiovascular mortality 11, 7
- Alirocumab specifically decreased adverse events leading to death (OR 0.79) 8
- Both agents decreased serious adverse events overall, driven mainly by alirocumab (OR 0.89) 8, 9
Important Clinical Considerations
Discontinuation Rates
- Adverse events leading to discontinuation are uncommon
- Injection site reactions leading to discontinuation: 15 per 1000 over 5 years 11
- Overall well-accepted by patients, including those intolerant to statins 1
Long-term Safety
- Safety data available up to 4-5 years of treatment 4, 12
- Longer-term safety beyond 4 years remains to be fully established, though available data are reassuring
- No new safety signals emerged in open-label extension studies 3
Drug Interactions
- No clinically significant drug-drug interactions identified for either alirocumab or evolocumab 6
Pregnancy and Lactation
- Insufficient data in pregnant women; avoid use during pregnancy 2, 3
- No information on presence in breast milk; consider risks/benefits of breastfeeding 3
- Animal studies showed no adverse effects on fetal development at exposures exceeding human doses 3